ArticleJTO clinical and research reports2022

A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC.

Sarina Piha-Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.